AlShammeri Saleh, AlKhaldi Saleh A, AlMutairi Reem T, AlZamil Hamad A, AlJohani Saad M, AlJohani Saeed, AlDakhil Sulaiman
Department of Optometry, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia.
Research Center, King Saud Medical City, Riyadh, Saudi Arabia.
Saudi J Ophthalmol. 2024 Aug 16;39(2):206-211. doi: 10.4103/sjopt.sjopt_305_23. eCollection 2025 Apr-Jun.
Comparison of the effectiveness between a lipid-based (Cationorm [CTN]) and nonlipid-based (Artelac Advanced, 0.2% sodium hyaluronate [SH]) tear supplements in the management of dry eye disease.
This was a randomized, single-masked study (0.2% SH vs. lipid-based eye drops) in two parallel groups over 4 weeks. = 44 patients were evaluated. The outcome of the tear supplements on the ocular surface symptoms, tear meniscus height (TMH), noninvasive tear break-up time (NITBUT), lipid layer thickness (LLT), corneal and conjunctival redness, and strip meniscometry tube (SMTube) were measured after 4 weeks, compared to baseline.
Compared to the baseline, a lipid-based (CTN) eye drop achieved a significant reduction in symptoms (14.25 ± 12.70 vs. 38.60 ± 23.13 score, = 22 patients) at 4 weeks; Artelac Advanced, 0.2% SH and CTN showed an improvement in TMH, but it was statistically significant improved in CTN group in compared to 0.2% SH group. Statistical analysis showed improvement in NITBUT and corneal and conjunctival redness in both treatment groups. At 4 weeks, the LLT had further increased in Artelac Advanced, 0.2% SH group. Both eye drops did not change the tear production measured by SMTube after 4 weeks.
Both lipid-based (CTN) and nonlipid-based Artelac Advanced, 0.2% SH eye drops effectively improved tear volume, tear film stability, and ocular surface health. In addition, lipid-based CTN significantly decreased dry eye symptoms compared to Artelac Advanced, 0.2% SH.
比较脂质型（Cationorm [CTN]）和非脂质型（Artelac Advanced，0.2%透明质酸钠[SH]）泪液补充剂在干眼症治疗中的有效性。
这是一项随机、单盲研究（0.2% SH与脂质型滴眼液），分为两个平行组，为期4周。共评估了44例患者。4周后，与基线相比，测量泪液补充剂对眼表症状、泪液半月皱襞高度（TMH）、无创泪膜破裂时间（NITBUT）、脂质层厚度（LLT）、角膜和结膜充血以及泪液半月皱襞试纸条（SMTube）的影响。
与基线相比，脂质型（CTN）滴眼液在4周时症状显著减轻（22例患者，评分从38.60±23.13降至14.25±12.70）；Artelac Advanced、0.2% SH和CTN均使TMH有所改善，但与0.2% SH组相比，CTN组改善具有统计学意义。统计分析显示，两个治疗组的NITBUT以及角膜和结膜充血均有改善。4周时，Artelac Advanced 0.2% SH组的LLT进一步增加。4周后，两种滴眼液均未改变SMTube测量的泪液分泌量。
脂质型（CTN）和非脂质型Artelac Advanced 0.2% SH滴眼液均能有效改善泪液量、泪膜稳定性和眼表健康。此外，与Artelac Advanced 0.2% SH相比，脂质型CTN能显著减轻干眼症状。
